123I FP-CIT SPECT Imaging in PD/PD+ and DLB
Research type
Research Study
Full title
123I FP-CIT SPECT Imaging in Parkinson’s Disease / Parkinson’s Plus and Lewy Body Dementia
IRAS ID
240738
Contact name
Alice Nicol
Contact email
Sponsor organisation
NHS Greater Glasgow & Clyde
Duration of Study in the UK
1 years, 0 months, 0 days
Research summary
123I FP-CIT SPECT imaging is used in the clinical pathway of patients with movement disorders, e.g. possible Parkinson’s Disease/Parkinson’s Plus (PD/PD+), or suspected Lewy Body Dementia (DLB). The movement disorder or type of dementia a patient has can be difficult to ascertain from the clinical presentation and may require further imaging to support a diagnosis.
All 123I FP-CIT SPECT DAT scans used will be retrospective, from patients clinically referred. These will be categorised into three scan appearances: normal, posterior-to-anterior progression, balanced reduction (note that there is sparse information on the latter of these). Clinical information will be collected based on diagnostic criteria for PD/PD+ and DLB. Each patient will have their clinical notes retrospectively analysed for the presence or absence of key clinical features. This will include reviewing Clinical Portal, EMIS (electronic mental health notes) and Medical and Psychiatric paper health records. Basic demographic information will also be obtained.
We will look for frequencies of the normal and two abnormal 123-I FP-CIT scan appearances and for associations between clinical features and these the scan appearances. Quantitative characteristics of the scan appearances will also be obtained.
It is hoped this information will lead to better understanding of 123I FP-CIT SPECT DAT scan imaging for the diagnosis for patients.REC name
West Midlands - Edgbaston Research Ethics Committee
REC reference
18/WM/0118
Date of REC Opinion
19 Apr 2018
REC opinion
Favourable Opinion